高级检索

留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

医用放射性同位素99Mo/99mTc生产现状和展望

李紫微 韩运成 王晓彧 张佳辰 王永峰 黄群英

李紫微, 韩运成, 王晓彧, 张佳辰, 王永峰, 黄群英. 医用放射性同位素99Mo/99mTc生产现状和展望[J]. 原子核物理评论, 2019, 36(2): 170-183. doi: 10.11804/NuclPhysRev.36.02.170
引用本文: 李紫微, 韩运成, 王晓彧, 张佳辰, 王永峰, 黄群英. 医用放射性同位素99Mo/99mTc生产现状和展望[J]. 原子核物理评论, 2019, 36(2): 170-183. doi: 10.11804/NuclPhysRev.36.02.170
LI Ziwei, HAN Yuncheng, WANG Xiaoyu, ZHANG Jiachen, WANG Yongfeng, HUANG Qunying. Production Status and Technical Prospects of Medical Radioisotope 99Mo/99mTc[J]. Nuclear Physics Review, 2019, 36(2): 170-183. doi: 10.11804/NuclPhysRev.36.02.170
Citation: LI Ziwei, HAN Yuncheng, WANG Xiaoyu, ZHANG Jiachen, WANG Yongfeng, HUANG Qunying. Production Status and Technical Prospects of Medical Radioisotope 99Mo/99mTc[J]. Nuclear Physics Review, 2019, 36(2): 170-183. doi: 10.11804/NuclPhysRev.36.02.170

医用放射性同位素99Mo/99mTc生产现状和展望

doi: 10.11804/NuclPhysRev.36.02.170
基金项目: 国家自然科学基金项目(11605232);安徽省自然科学基金项目(1808085MA10)
详细信息
    作者简介:

    李紫微(1995-),女,河北保定人,在读研究生,从事医用放射性同位素研究;E-mail:ziwei.li@fds.org.cn

    通讯作者: 韩运成,E-mail:yuncheng.han@fds.org.cn
  • 中图分类号: TL92

Production Status and Technical Prospects of Medical Radioisotope 99Mo/99mTc

Funds: National Natural Science Foundation of China (11605232); Anhui Provincial Natural Science Foundation (1808085MA10)
  • 摘要: 99mTc是目前临床诊断应用最为广泛的医用放射性同位素。现有医用99mTc主要通过在实验堆中辐照高浓缩235U生成的99Mo衰变得到,存在工艺复杂、成本高、长距离运输损失等弊端以及核扩散风险。此外,全球实验反应堆为数不多且面临老化、退役问题,也多次因计划内的维修或意外停产事件而使99mTc供应面临困难。本文从99Mo/99mTc的供求现状入手,分析了目前供应链中存在的主要问题,重点介绍了六种传统及新型99Mo/99mTc生产技术的原理、研究进展及其经济性效益。详细评述了三种99Mo/99mTc分离纯化工艺,提出了99Mo/99mTc生产的发展趋势和展望。其中,以加速器驱动裂变低浓缩铀盐溶液的生产方式具有无反应堆、无高浓缩铀、放射性废物少等优势,是未来的重点研究方向。同时,为减少99Mo/99mTc损失,提高产品质量,开发和优化与生产体系相适应的分离纯化工艺也势在必行。中国科学院核能安全技术研究所FDS中科凤麟核能团队设计开发的一种氘氚聚变中子源驱动的99Mo次临界生产系统方案,可获得27Ci/d的99Mo产量,能满足国内一个中等省份的医疗诊断需求。
  • [1] ZHANG Xianzhong. Study and Application of New Technetium-99m Labeled ISO Nitrile Complexes[D]. Beijing:Beijing Normal University, 2002(5):8. (in Chinese) (张现忠. 新型锝-99m标记异腈类配合物的研究及其应用[D]. 北京:北京师范大学, 2002(5):8.)
    [2] XIAO Fu. Technetium-the main force in clinical nuclear medicine diagnosis. Guangdong:Radiation Protection Association of Guangdong Province[EB/OL]. 2016-06-01. http://www.gdfushefanghuxiehui.com/menberview.asp?id=2&viewid=703. (in Chinese) (小辐. 锝——临床核医学诊断中的主力军[EB/OL]. 2016-06-01. 广东省:广东辐射防护协会. http://www.gdfushefanghuxiehui.com/menberview.asp?id=2&viewid=703
    [3] SOUTO F J, KIMPLAND R H, HEGER A S. Prenatal Diagnosis, 2005, 33(6):575.
    [4] ZHANG Yan. Foreign Nuclear News, 2011(6):28. (in Chinese) (张焰. 国外核新闻, 2011(6):28.)
    [5] AHMAD M, VANDEGRIFT G, CRISTINI P. Science & Technology of Nuclear Installations, 2013, 1:3.
    [6] WU Haosong. Foreign Nuclear News, 2016(12):16. (in Chinese) (伍浩松. 国外核新闻, 2016(12):16.)
    [7] LYRA M, CHARALAMBATOU P, ROUSSOU E, et al. Hellenic Journal of Nuclear Medicine, 2011, 14(1):49.
    [8] GAO Feng, LIN Li, LIU Yuhao, et al. Journal of Isotopes, 2012, 21(6):257. (in Chinese) (高峰, 林力, 刘宇昊, 等. 同位素, 2012, 21(6):257.)
    [9] WU Haosong. Foreign Nuclear News, 2011(6):28. (in Chinese) (伍浩松. 国外核新闻, 2011(6):28.)
    [10] LI Mingqi, DENG Qimin, CHENG Zuoyong, et al. Journal of Isotopes, 2013, 26(3):186. (in Chinese) (李明起, 邓启民, 程作用, 等. 同位素, 2013, 26(3):186.)
    [11] PONSARD B. Kernkraftwerke in Deutschland Betriebsergebnisse, 2015, 61(1):41.
    [12] ZOU Wei, YIN Hongyu, LIU Qiong. Chinese Journal of Nuclear Medicine and Molecular Imaging, 2016, 36(4):375. (in Chinese) (邹巍, 尹红玉, 刘琼. 中华核医学与分子影像杂志, 2016, 36(4):375.)
    [13] FILZEN M, ELLINGSON R, PAULSEN M, et al. Journal of Nuclear Medicine Technology, 2017, 45:1.
    [14] Non-HEU Production technologies for molybdenum-99 and technetium-99m[M]. Vienna:IAEA Nuclear Energy Series No.NF-T-5.4. ISBN 978-92-0-137710-4.
    [15] Opportunities and Approaches for Supplying Molybdenum-99 and Associated Medical Isotopes to Global Markets:Proceedings of a Symposium[C]. National Academies of Sciences, Engineering, and Medicine 2018 Washington, DC. The National Academies Press.
    [16] RYABCHIKOV A I, SKURIDIN V S, NESTEROV E V, et al. Nucl Instr and Meth B, 2004, 213(03):364.
    [17] KNAPP F, MIZADEH S. Europe Journal of Nuclear Medical 1994, 21(10):1151.
    [18] The Supply of Medical Radioisotopes:Review of Potential Molybdenum-99/Technetium-99m Production Technologies[M]. Vienna:Nuclear Energy Agency.2010. ISBN:978-92-64-99164-4.
    [19] ZYKOV M, ROMANOVSKⅡ N, WESTER D, et al. Radiochemistry, 2001, 43(3):297.
    [20] BALL R. Medical Isotope Production Reactor[P]. US:5596611,1997.01.21.
    [21] VALENTIN I. Research Reactors in Russia:Status and Prospects for Reducing the Fuel Enrichment, 2010.
    [22] PAVSHOOK V, KHVOSTIONOV V. International Meeting on Reduced Enrichment for Research and Test Reactors. October 18-23, 1998.
    [23] CHUVILIN D, KHVOSTIONOV V, MARKOVSKIJ D, et al. Applied Radiation and Isotopes, 2007, 65(10):1087.
    [24] Homogeneous Aqueous Solution Nuclear Reactors for the Production of Mo-99 and Other Short-lived Radioisotopes[M]. IAEA-TECDOC-1601, Vienna, Austria, September 2008 ISBN:978-92-0-109708-8.
    [25] LI Yunzhao, WU Hongchun, CAO Liangzhi, et al. Nuclear Power Engineering, 2009, 30(6):15.
    [26] DENG Qimin, LI Maoliang, CHENG Zuoyong. Chinese Journal of Nuclear Science and Engineering, 2006, 26(2):165. (in Chinese). (邓启民, 李茂良, 程作用. 核科学与工程, 2006, 26(2):165.)
    [27] CHABOD S, BLANDIN C, CHARTIER F, et al. Nucl Instr and Meth A. 2006, 562(2):618.
    [28] PANEBIANCO S, BEAUVAIS P, BRINGER O, et al. International Conference on Nuclear Data for Science and Technology 2007.
    [29] GREG C. Argonne National Laboratory. 2015.06.15.
    [30] CHEMERISOV S, YOUKER A, HEBDEN A, et al. Mo-99 topical meeting, December 4-7, 2011, New Mexico.
    [31] YOUKER A, CHEMERISOV S, TKAC P. Mo-99 Topical Meeting on Molybdenum-99 Technological Development, September 11-14, 2016, St. Louis, Missouri.
    [32] WU Yican. International Journal of Energy Research, 2017, 42:3572.
    [33] WU Yican, LIU Chao, SONG Gang, et al. Nuclear Science and Engineering, 2016, 36(1):77. (in Chinese) (吴宜灿, 刘超, 宋钢, 等. 核科学与工程, 2016, 36(1):77.
    [34] TKAC P, CHEMERISOV S, MAKARASHVILI V, et al. Mo-992013 Topical Meeting on Molybdenum-99 Technological Development. April 1-5, 2013, Chicago, Illinois.
    [35] FONG A, MEYER T, ZALA K. Task Force on Alternatives for Medical Isotope, October 19-20, 2008, Vancouver.
    [36] BUNATIAN G, NIKOLENKO V, POPOV A. Eprint arXiv:1012.5002, 2009.
    [37] BENNETT R, CHRISTIAN J, PETTI D, et al. Nuclear Technology, 1999, 126(1):102.
    [38] RICHARD V. Nature, 2013, 504(7479):202.
    [39] DALE G, CHEMERISOV S, VANDEGRIFT G, et al. AIP Conference Proceedings. American Institute of Physics, 2013:355.
    [40] WOLOSHUN K, DALE G, KELSEY C. 5th High Power Targetry Workshop, 2013(01):41.
    [41] SCHOLTEN B, LAMBRECHT R, COGNEAU M, et al. Applied Radiation and Isotopes, 1999, 51(1):69.
    [42] TAKACS S, SZUCS Z, TARKANYI F, et al. Journal of Radioanalytical and Nuclear Chemistry. 2003, 257(1):195.
    [43] GUERIN B, SEBASTIEN T, RODRIGUE S, et al. Journal of Nuclear Medicine, 2010, 51(4):13N.
    [44] Medical Isotope Production Without Highly Enriched Uranium[M]. Washington DC:National Academies Press, 2009.
    [45] SCHAFFER P, BENARD F, BERNSTEIN A, et al. Physics Procedia. 2015(66):383.
    [46] Nuclear Technology Review[M]. International Atomic Energy Agency, 2010, Vienna, Austria.
    [47] National Research Council (US) Committee on Medical Isotope Production Without Highly Enriched Uranium. Nonproliferation Review, 2009, 16(2):285.
    [48] XU Xiaofei, MA Hongli. Science & Technology Vision, 2014(22):8. (in Chinese) (许晓飞, 马红利. 科技视界, 2014(22):8.)
    [49] WALT T, COETZEE P. Radiochimical Acta/International Journal for Chemical Aspects of Nuclear Science & Technology, 2004, 92(4-6/2004):251.
    [50] WU D, LANDSBERGER S, VANDEGRIFT G. Office of Scientific & Technical Information Technical Reports, 1996.
    [51] HWANG D, CHOUNG W, KIM Y, et al. Journal of Radioanalytical & Nuclear Chemistry, 2002, 254(2):255.
    [52] WANG Qinggui, LIANG Jixin, WU Yuxuan. Journal of Isotopes, 2016, 29(4):216. (in Chinese) (王清贵, 梁积新, 吴宇轩. 同位素, 2016, 29(4):216.)
    [53] CHEMERISOV S, YOUKER A, HEBDEN, et al. Molybdenum-99 Topical Meeting. New Mexico December 4-7, 2011 La Fonda Hotel Santa Fe.
    [54] YOUKER A, CHEMERISOV S, TKAC P, et al. Journal of Nuclear Medicine Official Publication Society of Nuclear Medicine, 2016, 58(3):514.
    [55] YOUKER A, CHEMERISOV S, TKAC P. Mo-992016 Topical Meeting on Molybdenum-99 Technological Development. Sep11-14, 2016 St. Louis, Missouri.
    [56] MARTINI P, BOSCHI A, CICORIA G, et al. Applied Radiation and Isotopes, 2016, 118:302.
    [57] BOSCHI A, MARTINI P, PASQUALI M, et al. Drug Development and Industrial Pharmacy, 2017:1.
    [58] WU haosong. Foreign Nuclear News, 2016(4):1. (in Chinese) (伍浩松. 国外核新闻, 2016(4):1.)
  • 加载中
计量
  • 文章访问数:  3528
  • HTML全文浏览量:  471
  • PDF下载量:  428
  • 被引次数: 0
出版历程
  • 收稿日期:  2018-09-26
  • 修回日期:  2019-02-15
  • 刊出日期:  2019-06-20

医用放射性同位素99Mo/99mTc生产现状和展望

doi: 10.11804/NuclPhysRev.36.02.170
    基金项目:  国家自然科学基金项目(11605232);安徽省自然科学基金项目(1808085MA10)
    作者简介:

    李紫微(1995-),女,河北保定人,在读研究生,从事医用放射性同位素研究;E-mail:ziwei.li@fds.org.cn

    通讯作者: 韩运成,E-mail:yuncheng.han@fds.org.cn
  • 中图分类号: TL92

摘要: 99mTc是目前临床诊断应用最为广泛的医用放射性同位素。现有医用99mTc主要通过在实验堆中辐照高浓缩235U生成的99Mo衰变得到,存在工艺复杂、成本高、长距离运输损失等弊端以及核扩散风险。此外,全球实验反应堆为数不多且面临老化、退役问题,也多次因计划内的维修或意外停产事件而使99mTc供应面临困难。本文从99Mo/99mTc的供求现状入手,分析了目前供应链中存在的主要问题,重点介绍了六种传统及新型99Mo/99mTc生产技术的原理、研究进展及其经济性效益。详细评述了三种99Mo/99mTc分离纯化工艺,提出了99Mo/99mTc生产的发展趋势和展望。其中,以加速器驱动裂变低浓缩铀盐溶液的生产方式具有无反应堆、无高浓缩铀、放射性废物少等优势,是未来的重点研究方向。同时,为减少99Mo/99mTc损失,提高产品质量,开发和优化与生产体系相适应的分离纯化工艺也势在必行。中国科学院核能安全技术研究所FDS中科凤麟核能团队设计开发的一种氘氚聚变中子源驱动的99Mo次临界生产系统方案,可获得27Ci/d的99Mo产量,能满足国内一个中等省份的医疗诊断需求。

English Abstract

李紫微, 韩运成, 王晓彧, 张佳辰, 王永峰, 黄群英. 医用放射性同位素99Mo/99mTc生产现状和展望[J]. 原子核物理评论, 2019, 36(2): 170-183. doi: 10.11804/NuclPhysRev.36.02.170
引用本文: 李紫微, 韩运成, 王晓彧, 张佳辰, 王永峰, 黄群英. 医用放射性同位素99Mo/99mTc生产现状和展望[J]. 原子核物理评论, 2019, 36(2): 170-183. doi: 10.11804/NuclPhysRev.36.02.170
LI Ziwei, HAN Yuncheng, WANG Xiaoyu, ZHANG Jiachen, WANG Yongfeng, HUANG Qunying. Production Status and Technical Prospects of Medical Radioisotope 99Mo/99mTc[J]. Nuclear Physics Review, 2019, 36(2): 170-183. doi: 10.11804/NuclPhysRev.36.02.170
Citation: LI Ziwei, HAN Yuncheng, WANG Xiaoyu, ZHANG Jiachen, WANG Yongfeng, HUANG Qunying. Production Status and Technical Prospects of Medical Radioisotope 99Mo/99mTc[J]. Nuclear Physics Review, 2019, 36(2): 170-183. doi: 10.11804/NuclPhysRev.36.02.170
参考文献 (58)

目录

    /

    返回文章
    返回